Search Results - "Tence, N"
-
1
Percutaneous treatment of mitral regurgitation
Published in Annales de cardiologie et d'angeiologie (01-12-2019)“…Mitral regurgitation (MR) is currently the most frequent valvular heart disease, and the second most operated valve in Europe. Around 50% of patients…”
Get more information
Journal Article -
2
Prise en charge interventionnelle de la fuite mitrale
Published in Annales de cardiologie et d'angéiologie (31-12-2019)Get full text
Journal Article -
3
Impact of the cardio-hepatic syndrome on outcomes after transcatheter mitral valve edge-to-edge repair
Published in European heart journal (12-10-2021)“…Abstract Background The prognostic value of impaired liver function in the presence of moderate-to-severe and severe mitral regurgitation (MR), also called…”
Get full text
Journal Article -
4
P4550Simple renal cysts and aortic disease in Marfan syndrome and matched controls: prevalence and prognostic impact
Published in European heart journal (01-08-2018)Get full text
Journal Article -
5
P4544Prevalence of renal, hepatic, and pulmonary cysts in Marfan syndrome and matched controls: interest of a cystic score
Published in European heart journal (01-08-2018)Get full text
Journal Article -
6
P1646Do Extracellular Vesicles repair chronic ischemic heart disease by replenishing the cardiomyocyte pool?
Published in European heart journal (01-10-2019)“…Abstract Introduction Extracellular Vesicles (EV) seem to mediate the benefits of cell therapy for ischemic heart failure. Although their mechanism of action…”
Get full text
Journal Article -
7
How do Extracellular Vesicles Protect the Ischemic Myocardium?
Published in Cytotherapy (Oxford, England) (01-05-2020)“…Cell therapy for chronic heart failure has demonstrated that Cardiac Progenitor Cells (CPCs) delivered to the heart exert their beneficial effects through a…”
Get full text
Journal Article -
8
Prise en charge interventionnelle de la fuite mitrale
Published in Annales de cardiologie et d'angéiologie (01-12-2019)“…L’insuffisance mitrale (IM) est actuellement la valvulopathie la plus fréquente et la deuxième valvulopathie la plus opérée en Europe. Environ 50 % des…”
Get full text
Journal Article -
9